MMV533

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
MoA
  • Unknown, inability to select resistant mutants
Key features
  • Rapid parasite killing in vitro and clearance in vivo
  • Long predicted human half-life
  • Predicted dose to give coverage above Minimal Parasiticidal Concentration for >8 days is 80mg
Status
  • Preclinical development
Next milestone
  • Proceed to first-in-human studies
Previously
  • Full reference name is SAR 441121 (alternatively MMV688533)
MMV Project Director
  • Ilaria Di Resta